Kinnate Biopharma Inc. (KNTE) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
Address
103 Montgomery Street
San Francisco, CA 94129
United States of America (the)
Phone
858 299 4699
Website
Sector
Healthcare
Industry
Biotechnology
Employees
84
First IPO Date
December 03, 2020
| Name | Title | Pay | Year Born |
| Nima Farzan | President, Chief Executive Officer & Director | 891,954 | 1976 |
| Neha Krishnamohan | Chief Financial Officer, Principal Accounting Officer and Executive Vice President of Corporate Development | 548,950 | 1988 |
| Mark A. Meltz | Chief Operating Officer, General Counsel, Treasurer & Secretary | 671,864 | 1974 |
| Richard Thomas Williams | Chief Medical Officer | 0 | 1969 |
| Robert Kania | Senior Vice President of Research | 0 | N/A |
Kinnate Biopharma Inc. is a U.S.-based biopharmaceutical company primarily focused on identifying and advancing small-molecule drugs that target kinase enzymes to treat cancers defined by specific genetic markers. The company's product pipeline includes: KIN-2787: An inhibitor of rapidly accelerated fibrosarcoma (RAF), currently being developed to treat patients with lung cancer, melanoma, and other forms of solid tumors. KIN-3248: A small-molecule kinase inhibitor designed to counteract cancer-associated genetic mutations in the fibroblast growth factor receptors, specifically FGFR2 and FGFR3. KIN004 Program: This program encompasses early-stage small-molecule research, including a Cyclin-Dependent Kinase 12 (CDK12) inhibitor. Established in 2018, Kinnate Biopharma Inc. maintains its headquarters in San Francisco, California. It was formerly a division of Fount Therapeutics, LLC.